上海市广发律师事务所 关于上海皓元医药股份有限公司 2022 年限制性股票激励计划调整授予价格的 法律意见 电话：021-58358013|传真：021-58358012 网址：http://www.gffirm.com|电子信箱：gf@gffirm.com 办公地址：上海市南泉北路 429 号泰康保险大厦 26 层|邮政编码：200120 上海市广发律师事务所 关于上海皓元医药股份有限公司 2022 年限制性股票激励计划调整授予价格的法律意见 致：上海皓元医药股份有限公司 上海市广发律师事务所（以下简称"本所"）接受上海皓元医药股份有限公 司（以下简称"公司"）的委托，作为其实行 2022 年限制性股票激励计划事项（以 下简称"本次股权激励计划"）的专项法律顾问，就本次股权激励计划所涉限制 性股票授予价格调整事项，根据《中华人民共和国证券法》（以下简称"《证券法》"）、 《中华人民共和国公司法》（以下简称"《公司法》"）、中国证券监督管理委员会 （以下简称"中国证监会"）颁布的《上市公司股权激励管理办法》（以下简称"《管 理办法》"）、上海证券交易所发布的《上海证券交易所科创板股票上市规则》（以 下简称"《 ...

民生证券股份有限公司关于 上海皓元医药股份有限公司新增关联方及新增 2025 年度日常 关联交易预计的核查意见 民生证券股份有限公司（以下简称"民生证券"或"保荐机构"）作为上海 皓元医药股份有限公司（以下简称"皓元医药"或"公司"）向不特定对象发行 可转换公司债券的持续督导机构，根据《证券发行上市保荐业务管理办法》《上 海证券交易所科创板股票上市规则》及《上海证券交易所上市公司自律监管指引 第 1 号——规范运作》等有关法律法规和规范性文件的要求，对皓元医药新增关 联方及新增 2025 年度日常关联交易预计事项进行了核查，具体情况如下： 一、日常关联交易基本情况 （一）日常关联交易履行的审议程序 2025 年 4 月 28 日，公司 2025 年第四次董事会独立董事专门会议审议通过 《关于公司新增关联方及新增 2025 年度日常关联交易预计的议案》，独立董事认 为：公司与关联方签署协议并进行日常交易是为了满足日常生产经营的需要，属 于正常商业行为，遵循市场公允定价原则，且充分利用关联方拥有的资源为公司 的生产经营服务，有利于交易双方获得合理的经济效益，定价公允合理，未发现 损害公司及其他股东利益，不会对公司 ...

Financial Performance - In Q1 2025, the company achieved revenue of 606 million yuan, representing a year-on-year growth of 20.05% [1] - The net profit attributable to shareholders reached 62.38 million yuan, with a significant year-on-year increase of 272.28% [1] - The gross profit margin stood at 48.58%, an increase of 7.78 percentage points compared to the previous year [1] - As of the end of Q1, the company's total assets rose to 5.714 billion yuan [1] Industry Context - The global trade environment is undergoing profound changes, particularly due to escalating tensions in US-China trade relations [2] - The anticipated price increases for certain research service products from the US are expected to enhance the price competitiveness of domestic brands in China [2] - The domestic market is likely to see an acceleration in the process of domestic substitution, particularly in high-frequency repurchase products like research reagents [2] Business Development - The company has established a strong presence in the life sciences reagent sector, having developed over 37,000 products and accumulated more than 141,000 types of life science reagents [3] - The company operates eight business centers globally, serving over 13,000 clients, which solidifies its leading market position [3] - The front-end life sciences reagent business has shown robust growth, with its revenue share significantly increasing compared to the previous year [3] Innovation and Collaboration - The company is actively exploring the application of AI technology in new drug development, aiming to create an "AI + biomedicine" innovation hub [4] - A partnership with East China Normal University has been established to develop an "AI Drug Discovery Joint Laboratory," focusing on ADC drug database construction and AI-driven drug manufacturing [4] Backend Business and Global Strategy - The backend business is focused on specialty generic drug APIs and related intermediates, with a strong emphasis on meeting the growing demand for GMP commercial production capacity [5] - The company has launched a new ADC CDMO base in Chongqing, which provides comprehensive services from toxin synthesis to antibody conjugation and formulation [5] - The backlog of orders in the backend business has increased by over 30% year-on-year, indicating strong customer demand [5] Future Outlook - The company plans to deepen the operational efficiency and collaborative development of its three main business engines: tool compounds and biochemical reagents, molecular building blocks, and APIs and intermediates [6] - The focus for 2025 will be on sustainable high-quality development through co-creation and exploring new growth directions [6]

Core Insights - Shanghai Haoyuan Pharmaceutical Co., Ltd. reported a revenue of 606 million yuan for Q1 2025, representing a year-on-year growth of 20.05%, and a net profit attributable to shareholders of 62.38 million yuan, up 272.28% [1] - The total assets of the company reached 5.714 billion yuan by the end of Q1 [1] - The global trade environment is undergoing significant changes, with high-frequency repurchase characteristics of research reagents likely accelerating domestic substitution [1] Business Performance - The front-end life science reagent business of the company showed strong growth, with its revenue share significantly increasing compared to the same period last year [2] - The backlog of orders in the back-end business increased by over 30% year-on-year, indicating a notable rise in customer demand [2] Innovation and R&D - The company is actively exploring the application of AI technology in new drug development, aiming to establish an "AI + Biomedicine" innovation hub [2] - A partnership has been formed with East China Normal University to create an "AI Drug Exploration Joint Laboratory," focusing on ADC drug database construction and AI drug intelligent manufacturing [2] - The initiative aims to enhance the company's technological barriers in the entire drug development process and accelerate the transition of research results from the laboratory to production [2]

Core Viewpoint - The impact of the U.S. tariff policy on Chinese pharmaceutical companies is relatively limited, with many companies reporting normal operations and minimal effects from the tariffs [1][2][3][4][5]. Company Responses - Heng Rui Pharmaceutical stated that overseas sales account for only 2.56% of its revenue, indicating that U.S. tariffs will have a minimal impact on its business [1]. - Han Yu Pharmaceutical emphasized its diversified market layout, which mitigates risks from single market policy changes, and reported no significant impact from the tariffs [2]. - WuXi AppTec acknowledged that tariffs would have some effect but deemed it manageable, highlighting their optimized supply chain and global presence [3]. - Kang Tai Biological reported no exports to the U.S. and is focusing on markets along the Belt and Road, indicating a strategic shift to other regions [4]. - Mindray Medical confirmed that while some raw materials are imported from the U.S., they are taking measures to ensure supply safety and view the tariff impact as a one-time issue [4]. Industry Trends - The Chinese vaccine industry is rapidly developing, with companies like CanSino Biologics transitioning from followers to leaders in vaccine technology, focusing on domestic innovation [6][7]. - The overall sentiment among companies is that the tariff policy presents an opportunity for domestic product substitution, with many firms prepared to adapt to changing market conditions [5][8]. - Companies are increasingly focusing on technological innovation and expanding into emerging markets to counteract potential supply chain disruptions caused by tariffs [5][6][7].

Group 1: Haoyuan Pharmaceutical - Haoyuan Pharmaceutical emphasizes technological innovation as its core competitiveness, with plans to invest in R&D across multiple fields including anti-tumor and anti-viral areas in 2024 [1] - The company has completed the construction of a solid-phase platform for peptides, establishing a peptide CRO capability and developing over 600 compounds, along with a peptide drug production platform in Ma'anshan [1] - The molecular building block business is projected to achieve revenue of 420 million yuan in 2024, representing a year-on-year growth of 35.7%, with a reserve of 92,000 types of molecular building blocks and capabilities in customized R&D and global supply chain management [1] - Progress has been made in the construction of industrialization and CDMO bases in Jiangsu Qidong, Shandong Heze, Anhui Ma'anshan, and Chongqing, with some workshops already in operation [1] Group 2: Aladdin - Aladdin has achieved strong competitiveness through independent research and innovation, with several products realizing domestic substitution [2] - The company collaborates closely with Yuan Ye and Feipeng to share resources, expand business scale, and enhance overall competitiveness [2] - Cost control measures include promoting convertible bond conversions, optimizing inventory turnover, expanding overseas markets, and developing the biological reagent business [2] - Revenue growth in the life sciences segment is primarily driven by the merger with Yuan Ye Bio, which has increased sales of major life science products [2] - Both external and internal growth strategies are driving the company's development, with active research into potential acquisition projects [2] Group 3: Company Overview - Shanghai Panyao Asset Management Co., Ltd. was established on December 4, 2014, with a registered capital of 10 million yuan and holds a private equity license [3] - The firm focuses on long/short equity strategies and has issued over 100 products, with a cumulative registered scale exceeding 5 billion yuan [3] - Panyao Asset aims to manage financial wealth sustainably, emphasizing research-driven investment and a rigorous investment process [3] - The company seeks an ideal combination of top-down macro and industry allocation with bottom-up company selection in its investment strategy [3]

| 证券代码：688131 | 证券简称：皓元医药 | 公告编号：2025-051 | | --- | --- | --- | | 转债代码：118051 | 转债简称：皓元转债 | | 上海皓元医药股份有限公司 关于调整 2024 年度利润分配现金分红总额的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 现金分红总金额调整情况：上海皓元医药股份有限公司（以下简称"公 司"）2024 年度拟派发现金红利总额由 31,643,967.15 元（含税）调整为 31,636,808.40 元（含税）。 本次调整原因：因业绩补偿股份不参与公司本次现金分红，导致拟参与 利润分配的股份数量减少，公司拟维持每股分配金额不变，相应调整 2024 年度 现金分配总额。 一、调整前利润分配方案 如在利润分配方案公告披露之日起至实施权益分派股权登记日期间，因可 转债转股/回购股份/股权激励授予股份回购注销/重大资产重组股份回购注销等 1 致使公司总股本发生变动的，公司拟维持每股分配金额不变，相应调整分配总 额。如后续总股本 ...

证券之星消息，2025年4月11日皓元医药(688131)发布公告称公司于2025年4月7日接受机构调研，中金公 司（601995）、民生加银基金、中信证券、国投瑞银基金、鹏华基金、德邦证券、上投摩根基金、泰康资 产、兴业证券、招商基金、华泰证券、翊安投资参与。 具体内容如下： 问：美国加征对等关税对公司业务有何影响？公司如何应对？ 答：公司坚持全球化发展战略，经过多年的布局和推广，业务已遍及全球多个国家和地区，美国单一市场 营收占比较低。美国此次加征关税对公司的影响整体可控，公司经营情况一切正常。全球化、品牌化是公 司的重要发展战略，公司除了在美国之外，2023年在欧洲、印度建立了商务仓储中心，当前公司在积极开 拓日韩市场。公司海外已经储备了一定的产品，当前可以确保产品及时供应。公司也将密切关注国际环境 变化，积极加强新市场的开拓，灵活应对复杂多变的外部环境，保障公司的长期稳定发展。 2、请介绍下，公司自建产能爬坡情况，目前产能建设对后端业务的促进在收入上体现明显吗？ 公司后端业务主要聚焦于特色仿制药原料药及其相关中间体和创新药CDMO。2024年，公司凭借合理规 划，精准调控工程建设节奏，确保安徽马鞍山、 ...

Core Viewpoint - The annual general meeting of Shanghai Haoyuan Pharmaceutical Co., Ltd. was held on April 18, 2025, where all proposed resolutions were approved without any objections [2][5][6]. Meeting Details - The meeting took place at the company's conference room located at 1999 Zhangheng Road, Pudong New District, Shanghai [2]. - A total of 205,266,769 shares with voting rights were present at the meeting, excluding shares held in the employee stock ownership plan [2]. - The meeting was chaired by Director Gao Qiang, as Chairman Zheng Baofu attended via telecommunication [3][4]. Resolutions Passed - The following key resolutions were approved: - 2024 Annual Board Work Report [5] - 2024 Independent Director Work Report [6] - 2024 Supervisory Board Work Report [6] - 2024 Annual Report and Summary [6] - 2024 Financial Settlement Report [6] - 2025 Financial Budget Report [6] - Reappointment of the auditing firm for 2025 [6] - 2025 Director Remuneration [6] - 2025 Supervisor Remuneration [7] - 2025 Expected Daily Related Transactions [7] - 2024 Profit Distribution Plan [7] - 2025 Mid-Year Dividend Arrangement [7] - Performance Commitment and Compensation Plan for Yaoyuan Pharmaceutical [7] - Authorization for the Board to handle related matters for performance compensation share buyback [7]. Legal Compliance - The meeting's procedures and voting methods were confirmed to comply with the Company Law, Securities Law, and the company's articles of association [3][11]. - The legal representatives from Shanghai Guangfa Law Firm confirmed the legality and validity of the meeting and its resolutions [11]. Convertible Bond Information - The company plans to issue convertible bonds totaling 822.35 million yuan, with a net amount of 811.74 million yuan after deducting issuance costs [14][15]. - The bonds will be convertible into shares starting from June 4, 2025 [17]. - Investors must meet the suitability requirements for investing in the Sci-Tech Innovation Board to convert the bonds into shares [18]. Share Buyback Announcement - The company will repurchase and cancel 47,725 shares due to unmet performance commitments, reducing the total shares from 210,959,781 to 210,912,056 [23]. - Creditors are notified of the capital reduction and have the right to claim debts within specified timeframes [24].

| 证券代码：688131 | 证券简称：皓元医药 | 公告编号：2025-049 | | --- | --- | --- | | 转债代码：118051 | 转债简称：皓元转债 | | 上海皓元医药股份有限公司 2024年年度股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 4 月 18 日 （二） 股东大会召开的地点：上海市浦东新区张衡路 1999 弄 3 号楼公司会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 51 | | --- | --- | | 普通股股东人数 | 51 | | 2、出席会议的股东所持有的表决权数量 | 105,598,048 | | 普通股股东所持有表决权数量 | 105,598,048 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 51.4443 ...